The S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up 0.1% to 8,223.7 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:
Adairs Ltd (ASX: ADH)
The Adairs share price is up over 13% to $2.63. This has been driven by the release of the furniture and homewares retailer's first quarter update. Adairs reported a 4.8% year on year increase in unaudited sales for the first 16 weeks of FY 2025. This was driven almost entirely by the core Adairs brand, which reported sales growth of 8.6%. Mocka sales were up 0.4% and Focus on Furniture sales were down 3.7% over the same period last year. Management also revealed that its gross margin is up ~50 basis points on last year.
Chrysos Corporation Ltd (ASX: C79)
The Chrysos Corporation share price is up 7% to $5.03. This follows the release of the mining technology company's quarterly update. Chrysos reported unaudited revenue of $13.7 million for the first quarter. This represents 2% growth quarter on quarter and 54% year on year. Chrysos' CEO, Dirk Treasure, commented: "The first Quarter of 2025 not only saw Chrysos sign four new unit leases and deliver year-on-year sample and revenue growth of 30% and 54% respectively, it also marked the installation of our first USA-based PhotonAssay unit. This unit is the first of several deployments scheduled at the Barrick-Newmont NGM operation, representing Barrick's continuing adoption of our technology across its global network."
Karoon Energy Ltd (ASX: KAR)
The Karoon Energy share price is up 1.5% to $1.41. This morning, this energy producer released its third quarter update and revealed a 25% increase in quarterly production compared to the second quarter. This reflects a 44% increase in Bauna production, which helped offset a 10% decline in Who Dat production. The latter was impacted by seasonal hurricane-related shut-ins and planned maintenance. Also going down well with shareholders is news that the company's board has announced another US$25 million share buyback.
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix Pharmaceuticals share price is up almost 4% to $21.90. This follows news that the United States Food and Drug Administration (FDA) has accepted Telix's New Drug Application (NDA) for Pixclara. It is an agent for the imaging of glioma. Telix executive, Kevin Richardson, said: "Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the U.S., and bring it into line with a more advanced standard of care currently used in other markets."
